NCT05182476 (ERUDITE) is a Phase 2 clinical trial of Luvadaxistat in Schizophrenia, sponsored by Neurocrine Biosciences.

Who is sponsoring NCT05182476?

NCT05182476 is sponsored by Neurocrine Biosciences.

What drugs are being tested in NCT05182476?

Interventions in NCT05182476: Placebo, Luvadaxistat.

What condition does NCT05182476 study?

NCT05182476 studies Schizophrenia.

Is NCT05182476 still recruiting?

NCT05182476 is currently terminated. Last updated 2 July 2025.

Last reviewed 2025-07-02 · How we verify

NCT05182476: ERUDITE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

Terminated Phase 2 Last updated 2 July 2025

What this trial tests

Phase 2 trial testing Placebo in Schizophrenia in 216 participants. Terminated before completion.

Timeline

7 December 2021

Primary endpoint
28 June 2024

14 October 2024

Quick facts

Lead sponsor	Neurocrine Biosciences
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	216
Start date	7 December 2021
Primary completion	28 June 2024
Estimated completion	14 October 2024
Sites	49 locations across Serbia, Bulgaria, United States, Spain, Czechia

Drugs / interventions tested

Placebo
Luvadaxistat — full drug profile →

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

Neurocrine Biosciences — full company profile →

Who can join

Adults 18 to 50, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.
Rosenbrock H, Desch M, Wunderlich G. · · 2023 · cited 56× · PMID 36971864 · DOI 10.1007/s00406-023-01576-z
New Developments in the Treatment of Schizophrenia: An Expert Roundtable.
Kantrowitz JT, Correll CU, Jain R, Cutler AJ. · · 2023 · cited 23× · PMID 36932673 · DOI 10.1093/ijnp/pyad011
Novel Compounds in the Treatment of Schizophrenia-A Selective Review.
Tsapakis EM, Diakaki K, Miliaras A, Fountoulakis KN. · · 2023 · cited 21× · PMID 37626549 · DOI 10.3390/brainsci13081193
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.
Veselinović T, Neuner I. · · 2022 · cited 18× · PMID 35831706 · DOI 10.1007/s40263-022-00935-z
Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives.
Vita A, Nibbio G, Barlati S. · · 2024 · cited 13× · PMID 39144119 · DOI 10.1093/schizbullopen/sgae013
Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement.
Sehatpour P, Kantrowitz JT. · · 2025 · cited 12× · PMID 39218136 · DOI 10.1016/j.biopsych.2024.08.019
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds.
Biso L, Carli M, Scarselli M, Longoni B. · · 2025 · cited 8× · PMID 39857669 · DOI 10.3390/biomedicines13010085
Therapeutic potential of D-amino acid oxidase inhibitors for cognitive impairment associated with schizophrenia: learnings from luvadaxistat.
Terry-Lorenzo RT, Fan RH, Khin NA, Singh JB. · · 2024 · cited 5× · PMID 39756412 · DOI 10.1093/ijnp/pyae066

Verify or expand the search:

Other trials of Luvadaxistat

Trials testing the same drug.

NCT03359785 — A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia · Phase 2 · completed
NCT03382639 — A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia · Phase 2 · completed

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Neurocrine Biosciences trials

Trials by the same sponsor.

NCT07187375 — Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Le · Phase 2 · recruiting
NCT06267846 — A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder · Phase 2 · completed
NCT05859698 — Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyski · Phase 4 · completed
NCT05654870 — Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia · Phase 3 · terminated
NCT05493293 — Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05182476 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neurocrine Biosciences
Last refreshed: 2 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05182476.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing